The peroxisome proliferator nafenopin does not suppress hepatocyte apoptosis in guinea-pig liver in vivo nor in human hepatocytes in vitro

Archives of Toxicology

Volumn 72, Issue 12, 1998, Pages 777-783

  Hasmall, Susan C ^a   James, Neil H ^a   Soames, Anthony R ^a   Roberts, Ruth A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Apoptosis; Nafenopin; Peroxisome proliferation; Species differences

Indexed keywords

CARCINOGEN; NAFENOPIN; PEROXISOME PROLIFERATOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME INDUCTION; GUINEA PIG; HAMSTER; HUMAN; HUMAN CELL; LIPID METABOLISM; LIVER CARCINOGENESIS; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SPECIES DIFFERENCE;

ANIMALS; APOPTOSIS; CELLS, CULTURED; DEPRESSION, CHEMICAL; DNA; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HUMANS; LIVER; MALE; NAFENOPIN; PEROXISOME PROLIFERATORS; RISK ASSESSMENT; SPECIES SPECIFICITY;

EID: 0032419776     PISSN: 03405761     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002040050573     Document Type: Article

References (43)

1. Ashby J, Brady A, Elcombe CR, Elliot BM, Ishmael J, Odum J, Tugwood JD, Keule S, Purchase IFH (1994) Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum Exp Toxicol 13: S1-S117
2. Bayly AC, Roberts RA, Dive C (1994) Suppression of liver cell apoptosis in vitro by the non-genotoxic hepatocarcinogen and peroxisome proliferator, nafenopin. J Cell Biol 125: 197-203
3. Bell AR, Savory R, Horley NJ, Choudhury AI, Dickens M, Gray TJB, Salter AM, Bell DR (1998) Molecular basis of non-responsiveness to peroxisome proliferators: the guinea-pig PPARα is functional and mediates peroxisome proliferator-induced hypolipidaemia. Biochem J 332: 689-693
4. Bentley P, Calder I, Elcombe C, Grasso P, Wiegand HG, Stringer DA (1992) Hepatic peroxisome proliferation, Monograph 17. European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels
5. Bieri F, Bentley P, Waechter F, Staubli W (1984) Use of primary cultures of adult rat hepatocytes to investigate mechanisms of action of nafenopin, a hepatocarcinogenic peroxisome proliferator. Carcinogenesis 5: 1033-1039
6. Bojes HK, Thurman RG (1996) Peroxisome proliferators activate kupffer cells in vivo. Cancer Res 56: 1-4
7. Bursch W, Dusterberg B, Schulte-Hermann R (1986) Growth, regression and cell death in rat liver as related to tissue levels of the hepatomitogen cyproterone acetate. Arch Toxicol 59: 221-227
8. Cunningham ML (1996) Role of increased DNA replication in the carcinogenic risk of nonmutagenic chemical carcinogens. Mutat Res 365: 59-69
9. Eacho PI, Foxworthy PS, Dillard RD, Whitesitt CA, Herron DK, Marshall WS (1986) Hepatic peroxisomal changes induced by tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Toxicol Appl Pharmacol 83: 430-437
10. Elcombe CR (1985) Species differences in carcinogenicity and peroxisome proliferation due to trichloroethylene: a biochemical human hazard assessment. Arch Toxicol (Suppl) 8: 6-17
11. Elcombe CR, Mitchell A (1986) Peroxisome proliferation due to di(2-ethyhexyl) phthalate: species differences and possible mechanisms. Environ Health Perspect 70: 211-219
12. Flecknell PA (1996) Laboratory animal anaesthesia, 2nd edn. Academic Press, London
13. Foxworthy PS, White SL, Hoover DM, Eacho PI (1990) Effects of ciprofibrate, bezafibrate and LY171883 on peroxisomal beta-oxidation in cultured rat, dog and rhesus monkey hepatocytes. Toxicol Appl Pharmacol 104: 386-394
14. Gerbracht U, Bursch W, Kraus P, Putz B, Reinacher M, Timmerman-Trosiener I, Schulte-Hermann R (1990) Effects of the hypolipidaemic drugs nafenopin and clofibrate on phenotypic expression and cell death (apoptosis) in altered foci of rat liver. Carcinogenesis 11: 617-624
15. Gorczyca W, Gong J, Darzynkiewicz Z (1993) Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 53: 1945-1951
16. Gray JB, Lake BG, Beamand JA, Foster JR, Gangoli SD (1983) Peroxisome proliferation in primary cultures of rat hepatocyte. Toxicol Appl Pharmacol 67: 15-25
17. Hanefeld M, Hemmer C, Kadner E (1983) Relationship between morphological changes and lipid lowering action of pchlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 46: 239-246
18. Hertz R, Bishara-Shieban J, Bar-Tana J (1995) Mode of action of peroxisome proliferators as hypolipidemic drugs. J Biol Chem 270: 13470-13475
19. Holden PR, Tugwood JD (1998) Peroxisome proliferator-activated receptor alpha (PPARα) role in rodent liver cancer and species differences. J Mol Endocrinol (in press)
20. Iqbal S, Elcombe CR, Elias E (1991) Maintenance of mixed-function oxidase and conjugation enzyme activities in hepatocyte cultures prepared from normal and diseased human liver. Hepatology 12: 336-343
21. Ismail T, Howl J, Wheatley M, McMaster P, Neuberger JM, Strain AJ (1991) Growth of normal human hepatocytes in primary culture: effect of hormones and growth factors on DNA synthesis. Hepatology 14: 1076-1082
22. James NH, Roberts RA (1996) Species differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than with suppression of apoptosis. Carcinogenesis 17: 1623-1632
23. Lake BG (1995) Mechanisms of hepatocarcinogenicity of peroxisomes-proliferating drugs and chemicals. Annu Rev Pharmacol Toxicol 35: 483-507
24. Lake BG, Evans JG, Gray TJB, Korosi SA, North CJ (1989) Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea-pig and marmoset. Toxicol Appl Pharmacol 99: 148-160
25. Lee S.-T, Pineau T, Drago J, Lee EJ, Owens JO, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ (1995) Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotrophic effects of peroxisome proliferators. Mol Cell Biol 15: 3012-3022
26. Li AP, Myers CA, Roque MA, Kaminski DL (1991) Epidermal growth factor, DNA synthesis and human hepatocytes. In Vitro Cell Dev Biol Anim 27(A): 831-833
27. Makowska JM, Bonner FW, Gibson GG (1991) Comparative induction of cytochrome P450IVA1 and peroxisome proliferation by ciprofibrate in the rat and marmoset. Arch Toxicol 65: 106-113
28. Mitchell AM, Bridges JW, Elcombe CR (1984) Factors influencing peroxisome proliferation in cultured rat hepatocytes. Arch Toxicol 55: 239-246
29. Moody DE, Reddy JK, Lake BG, Popp JA, Reese DH (1991) Peroxisome proliferation and non-genotoxic carcinogenesis: commentary on a symposium. Fundam Appl Toxicol 6: 233-248
30. Oberhammer FA, Roberts RA (1994) Apoptosis: a widespread process involved in liver adaptation and carcinogenesis. In: Arias IM, Boyer JL, Faust N, Jakoby WB, Schachter D, Shafritz DA, (eds) The liver: Biology and pathobiology Raven Press New York, pp 1547-1556
31. Pacot C, Petit M, Rollin M, Behechti N, Moisant M, Deslex P, Althoff J, Lhuguenot JC, Latruffe N (1996) Differences between guinea-pig and rat in the liver peroxisomal response to equivalent plasmatic level of ciprofibrate. Arch Biochem Biophys 327: 181-188
32. Parzefall W, Erber E, Sedivy R, Shulte-Hermann R (1991) Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumour promotors. Cancer Res 51: 1143-1147
33. Plant NJ, Horley NJ, Savory RL, Elcombe CR, Gray TJB, Bell DR (1998) The peroxisome proliferators are hepatocyte mitogens in chemically-defined media: glucocorticoid-induced PPARα is linked to peroxisome proliferator mitogenesis. Carcinogenesis 19: 925-931
34. Price RJ, Evans JG, Lake BG (1992) Comparison of the effects of nafenopin on hepatic peroxisome proliferation and replicative DNA synthesis in the rat and Syrian hamster. Fd Chem Toxicol 30: 937-944
35. Reddy JK, Azarnoff DL, Hignite CE (1980) Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283: 397-398
36. Roberts RA (1996) Non-genotoxic hepatocarcinogenesis: suppression of apoptosis by peroxisome proliferators. In: Reddy JK, Suga T, Mannearts GP, Lazarow PB, Subramani S, (eds) Peroxisomes: biology and role in toxicology and disease, vol 804. New York Academy of Sciences, New York, pp 588-602
37. Roberts RA, Soames AR, Gill JH, James NH, Wheeldon EB (1995) Non-genotoxic hepatocarcinogens stimulate DNA synthesis and their withdrawal induces apoptosis, but in different discrete hepatocyte populations. Carcinogenesis 16: 1693-1698
38. Rusyn I, Tsukamoto H, Thurman RG (1998) WY-14 643 rapidly activates nuclear factor kappa b in Kupffer cells before hepatocytes. Carcinogenesis 19: 1217-1222
39. Schoonjans K, Staels B, Auwerx J (1996) Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 905-925
40. Schulte-Hermann R, Hoffann V, Parzefall W, Kallenbach M, Gerhardt A, Schuppler J (1980) Adaptive responses of the liver to the gestagen and anti-androgen cyproterone acetate and other inducers. II. Induction of growth. Chem Biol Interact 31: 287-300
41. Watanabe T, Horie S, Yamada J, Isaji M, Nishigaki T, Naito J, Suga T (1989) Species differences in the effects of bezafibrate, a hypolipidaemic agent, on hepatic peroxisome associated enzymes. Biochem Pharmacol 38: 430-437
42. Wheeldon E, Williams S, Soames A, James N, Roberts RA (1995) Quantitation of apoptotic bodies by in situ end labelling (ISEL): correlation with morphology. Toxicol Pathol 23: 410-415
43. Williams GM, Perrone C (1995) Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. In: Reddy JK, Suga T, Mannaerts GP, Lazarow PB, Subramani S, (eds) New York Academy of Sciences New York, pp 554-572